Kevin Joseph Fitzgerald Sells 2,441 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares in the company, valued at $11,405,673.55. This trade represents a 8.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, August 18th, Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of ALNY opened at $456.35 on Friday. The business’s 50 day moving average is $441.57 and its 200 day moving average is $339.35. The company has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ALNY. Jefferies Financial Group lifted their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research note on Monday, July 7th. HC Wainwright reissued a “buy” rating and set a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Evercore ISI increased their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research note on Thursday, September 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Saturday, September 27th. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Twenty-four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $439.58.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Wealth Enhancement Advisory Services LLC increased its holdings in Alnylam Pharmaceuticals by 94.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company’s stock worth $2,957,000 after purchasing an additional 6,112 shares during the period. Merit Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 113.0% during the 1st quarter. Merit Financial Group LLC now owns 5,314 shares of the biopharmaceutical company’s stock worth $1,435,000 after purchasing an additional 2,819 shares during the period. Whipplewood Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 71 shares during the period. Finally, TB Alternative Assets Ltd. purchased a new position in Alnylam Pharmaceuticals during the 1st quarter worth $2,476,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.